Clinical Trials Logo

ALK Fusion Protein Expression clinical trials

View clinical trials related to ALK Fusion Protein Expression.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05950139 Recruiting - NSCLC Stage IV Clinical Trials

Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Start date: May 13, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

NCT ID: NCT04921553 Recruiting - Cancer Clinical Trials

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

TRacKING
Start date: June 22, 2021
Phase:
Study type: Observational [Patient Registry]

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion. This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.